Guardian Therapeutics

Bringing to life the full potential of aptamer therapeutics.

Aptamers

  • Aptamers are short nucleic acids that bind to a specific target molecule
  • The word aptamer comes from the Latin aptus meaning fit
  • At the molecular level, aptamers bind to their target site through electrostatic interactions, hydrophobic interactions, and their complementary shapes
  • Aptamers have been discovered that are specific to small molecules, proteins, nucleic acids, cells, tissues and organisms

BT100 aptamer:vWF A1 domain complex

...

ApDC

Aptamer Drug Conjugates: A Novel Targeted Delivery Platform for Oncology

...

Targeted therapy modality in which aptamers replace mAbs in drug conjugates

Have target specificity and affinity on par with mAbs

Can be selected for inhibitory, stimulatory, or no biological activity

Support receptor-mediated internalization

Different aptamers may be joined to form bi-specific therapeutic agents

Therapeutic Areas & Programs

We focus on six difference therapeutic areas and programs, each with their own targets.

Hematology
Hematology
Oncology ADC
Cardiovascular
Oncology ADC
Oncology ApDC
Immuno-Oncology
Immuno-Oncology
Immunology
Immunology
Gastrointestinal
Gastrointestinal

Revolutionizing Discovery Of Aptamer Therapeutics


Rapid Aptamer Discovery Process

Deep Sequencing

Therapeutic-relevant Nucleotide Chemistries

High-throughput Aptamer Synthesis

home-discovery-aptamer

Our People

Meet the leaders who are innovating Aptamer Therapeutics

Team Graphic

Contact

© 2021 Guardian Therapeutics. All rights reserved.

Headquarters
Guardian Therapeutics
101 Hartwell Avenue
Suite 2
Lexington, MA 02421
+1 (781) 918-6580

General Inquiries:
info@guardian-rx.com

Business Development Inquiries: businessdevelopment@guardian-rx.com